Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 913
interventional 826
Observational 76
Registry 11

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 441
Biological 69
Biological|Drug 62
Drug|Other 48
Biological|Drug|Other 36
Biological|Drug|Procedure|Radiation 18
Drug|Procedure 14
Biological|Other 13
Drug|Other|Procedure|Radiation 13
Procedure 11
Biological|Drug|Other|Procedure|Radiation 10
Drug|Procedure|Radiation 9
Drug|placebo 8
Biological|Drug|Radiation 6
Biological|Other|Procedure 5
Combination Product 5
Drug|Genetic 4
Drug|Radiation 4
Other 4
Biological|Drug|Genetic|Other 3
Biological|Drug|Other|Procedure 3
Biological|Drug|Procedure 3
Biological|Procedure 3
Dietary Supplement|Other 3
Drug|Other|Procedure 3
Biological|Drug|Genetic|Other|Procedure 2
Biological|Other|placebo 2
Drug|Genetic|Other 2
Other|Procedure 2
Behavioral 1
Behavioral|Dietary Supplement|Other 1
Biological|Device 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Device|Drug|Radiation 1
Biological|Dietary Supplement|placebo 1
Biological|Drug|Other|Radiation 1
Biological|Drug|placebo 1
Biological|Genetic|Other 1
Biological|Genetic|Other|Procedure 1
Biological|Procedure|Radiation 1
Device 1
Device|Drug 1
Device|Drug|Procedure|Radiation 1
Dietary Supplement 1
Dietary Supplement|Drug|Other 1
Dietary Supplement|placebo 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo|Procedure 1
Genetic 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 519
China 29
Germany 23
NA 13
France 12
United Kingdom 12
Canada 9
Italy 9
United States|Canada 9
Japan 8
Austria 7
Sweden 7
Spain 6
United States|Australia 6
United States|Italy 6
United States|Germany|Italy 5
Austria|Germany 4
United States|Germany 4
United States|United Kingdom 4
Korea, Republic of 3
Austria|France|Germany 2
Denmark 2
Germany|Austria 2
Lithuania 2
Spain|United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Czechia|Denmark|Egypt|Estonia|France|Germany|Hong Kong|Italy|Mexico|Netherlands|New Zealand|Romania|Russian Federation|Slovakia|Switzerland|Thailand|United Kingdom 2
Switzerland 2
United States|Australia|Austria|Belgium|France|Germany|Hungary|Italy|New Zealand|Spain|United Kingdom 2
United States|Australia|Belgium|Canada|China|Czechia|Ireland|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Turkey|Ukraine|United Kingdom 2
United States|Australia|France|Poland 2
United States|Denmark|Germany 2
United States|Italy|United Kingdom 2
United States|Switzerland 2
Argentina|Australia|Brazil|Canada|Chile|Croatia|Czechia|France|Germany|Greece|Italy|Mexico|New Zealand|Poland|Portugal|Russian Federation|Slovakia|Spain|Turkey 1
Argentina|Australia|Bulgaria|Hong Kong|Hungary|Mexico|New Zealand|Poland|Russian Federation|Taiwan 1
Argentina|Belgium|Bosnia and Herzegovina|Brazil|Canada|Egypt|Estonia|Finland|France|Germany|Greece|Ireland|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Mexico|North Macedonia|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|Slovenia|Spain|Sweden|Switzerland|Thailand|Turkey 1
Argentina|Croatia|Greece|Ireland|Italy|New Zealand|Russian Federation|United Kingdom 1
Argentina|Venezuela 1
Australia 1
Australia|Austria|Belgium|Czech Republic|Denmark|France|Germany|Israel|Italy|New Zealand|Spain 1
Australia|China|New Zealand|Taiwan 1
Australia|France|Germany|Hungary|Korea, Republic of|Poland|Singapore|United Kingdom 1
Australia|Poland 1
Austria|Belgium|Bulgaria|Czechia|France|Germany|Hungary|Ireland|Israel|Italy|Poland|Russian Federation|Singapore|Slovakia|Sweden|Ukraine|United Kingdom 1
Austria|Belgium|France|Italy 1
Austria|Brazil|United States|Argentina|Australia|Bulgaria|Canada|Croatia|Czechia|Denmark|Egypt|Estonia|France|Germany|Hong Kong|Italy|Mexico|Netherlands|New Zealand|Romania|Russian Federation|Slovakia|Spain|Switzerland|Thailand|United Kingdom 1
Austria|Czechia|Slovakia 1
Belarus|Poland 1
Belgium 1
Belgium|Canada|China|France|Hungary|Italy|Netherlands|Poland|Spain|United Kingdom 1
Belgium|Denmark|Netherlands 1
Belgium|France|Germany 1
Belgium|France|Spain 1
Belgium|France|United States|Israel|Spain|United Kingdom 1
Bulgaria|Georgia|Poland 1
Canada|France 1
Canada|Germany 1
Canada|Russian Federation|Spain 1
China|Malaysia|Australia|Taiwan 1
China|Philippines|Taiwan|Thailand|Vietnam 1
Czech Republic 1
Czechia|Denmark|France|Germany|Hungary|Israel|Italy|United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Korea, Republic of|Netherlands|Poland|Russian Federation|Saudi Arabia|Slovakia|South Africa|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
Denmark|Netherlands|Spain|United Kingdom 1
Finland 1
France|United Kingdom 1
Germany|Austria|Belgium|Denmark|Finland|Ireland|Israel|Netherlands|Sweden|Switzerland 1
Germany|Netherlands|United Kingdom 1
Greece 1
Hong Kong 1
India 1
Ireland 1
Israel 1
Japan|Korea, Republic of 1
Mexico 1
Poland 1
Poland|Spain 1
Poland|United Kingdom 1
Russian Federation 1
Spain|Finland|France|Portugal|Sweden|Tunisia|Turkey|United Kingdom 1
Spain|United States|Australia|Austria|Belgium|Canada|Colombia|Czechia|Denmark|France|Germany|Hungary|Ireland|Israel|Italy|Mexico|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|South Africa|Sweden|United Kingdom 1
Spain|United States|Australia|Belgium|Denmark|France|Germany|Hungary|Israel|Italy|Netherlands|New Zealand|Poland|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Denmark|Estonia|France|Germany|Italy|Mexico|New Zealand|Poland|Romania|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada 1
United States|Argentina|Belgium|Brazil|Canada|Colombia|Czechia|France|Germany|Greece|Israel|Korea, Republic of|Mexico|Poland|Portugal|Russian Federation|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Colombia|Croatia|Czechia|Denmark|France|Hungary|Israel|Italy|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|South Africa|Spain|United Kingdom 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Croatia|Czechia|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Russian Federation|Singapore|Slovakia|Spain|Sweden|Taiwan|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Czechia|France|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|France|Ireland|Italy|Poland|Spain|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Chile|Colombia|France|Germany|Hungary|Israel|Italy|Lithuania|New Zealand|Poland|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Canada|Croatia|Czechia|France|Greece|Hungary|Ireland|Italy|Poland|Portugal|Romania|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Denmark|France|Hungary|Italy|Netherlands|New Zealand|Norway|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Canada|Germany|New Zealand|Sweden|Turkey|United Kingdom 1
United States|Australia|Belgium|China|Czechia|France|Germany|Italy|Netherlands|New Zealand|Poland|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Belgium|France|Germany|Italy|Netherlands|Puerto Rico|United Kingdom 1
United States|Australia|Brazil|Canada|Denmark|Finland|France|Germany|Italy|Korea, Republic of|Netherlands|Norway|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Brazil|Czech Republic|France|Israel|Italy|Poland|Puerto Rico|Russian Federation|Ukraine|United Kingdom 1
United States|Australia|Canada|France|Germany|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Poland|United Kingdom 1
United States|Australia|France|Germany|Israel|Korea, Republic of|Spain 1
United States|Australia|France|Italy|Spain 1
United States|Australia|Germany|United Kingdom 1
United States|Australia|Israel|Poland|Ukraine 1
United States|Australia|Italy|New Zealand|Spain 1
United States|Australia|New Zealand 1
United States|Austria 1
United States|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Netherlands|Norway|Portugal|Puerto Rico|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Austria|Bulgaria|Canada|Croatia|France|Germany|Greece|Italy|Poland|Portugal|Romania|Russian Federation|Sweden|Ukraine 1
United States|Austria|Germany|Italy|Poland|United Kingdom 1
United States|Austria|Germany|Italy|Spain 1
United States|Austria|Germany|Poland|Spain 1
United States|Belgium|Canada|Czechia|Denmark|France|Israel|Netherlands|Poland|Russian Federation|Spain|Sweden|Turkey|United Kingdom 1
United States|Belgium|Canada|France|Germany|Israel|Italy|Poland 1
United States|Belgium|Czech Republic|France|Serbia|United Kingdom 1
United States|Belgium|Czech Republic|Greece|Italy|Poland|Russian Federation|Spain 1
United States|Brazil|Bulgaria|Canada|Germany|Greece|India|Italy|Mexico|Netherlands|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Canada|France|Germany|Italy|Spain|Sweden|United Kingdom 1
United States|Canada|France|Netherlands 1
United States|Canada|Georgia|Moldova, Republic of|Poland|Spain|Ukraine 1
United States|Canada|Germany|Italy|Spain|Sweden|United Kingdom 1
United States|Canada|Puerto Rico|South Africa 1
United States|Denmark 1
United States|Denmark|France|United Kingdom 1
United States|Denmark|Italy 1
United States|France 1
United States|France|Germany 1
United States|France|Germany|Italy|Japan|Netherlands|United Kingdom 1
United States|France|Germany|Italy|Poland|United Kingdom 1
United States|France|Germany|Italy|United Kingdom 1
United States|France|Germany|Spain 1
United States|Germany|Italy|Spain 1
United States|Israel 1
United States|Israel|Italy|Poland|Russian Federation|Spain|United Kingdom 1
United States|Italy|Poland|United Kingdom 1
United States|Japan 1
United States|Poland 1
United States|Puerto Rico|South Africa 1
United States|Sweden 1

Sites per Study

Site_count Study_Count
1 388
2 71
3 42
4 22
5 26
6 26
7 19
8 10
9 8
10 19
11 24
12 16
13 8
14 5
15 5
16 4
17 6
18 5
19 5
20 5
21 4
22 4
23 7
24 1
25 4
26 3
27 2
28 1
30 2
31 2
32 1
33 3
34 5
35 2
36 1
38 1
39 1
41 2
44 1
46 1
48 4
50 1
51 1
52 1
53 1
54 2
55 1
57 1
58 1
67 1
69 1
71 2
72 1
75 1
76 1
79 1
80 1
84 1
85 1
86 1
87 1
88 1
91 1
92 1
103 1
106 2
107 1
108 2
111 1
117 1
123 1
125 1
135 2
145 2
150 2
160 3
161 1
162 1
164 1
165 1
174 1
196 1
218 1
241 1
262 3
364 1
747 1
796 1
837 1
954 1

Phase

Phase Study_Count
Phase 2 345
Phase 1 236
Phase 1/Phase 2 121
Phase 3 82
N/A 23
Early Phase 1 11
Phase 4 6
Phase 2/Phase 3 2

Number of Arms

Number_of_Arms Count_of_Studies
1 488
2 156
3 51
4 27
5 8
6 3
7 3
8 3
10 2
11 1
NA 84

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 4.00000 5.0000 2.00000 1.00000 1.00000 11.00 20.00 10.00000
1st Qu. 9.00000 28.5000 19.25000 30.00000 28.00000 32.25 171.75 22.25000
Median 18.00000 55.0000 33.00000 44.00000 46.00000 53.50 318.00 30.50000
Mean 44.54545 105.4348 51.06838 64.63025 66.25826 53.50 401.35 87.16667
3rd Qu. 31.50000 115.0000 60.00000 80.50000 82.00000 74.75 549.25 64.25000
Max. 312.00000 713.0000 746.00000 403.00000 418.00000 96.00 1337.00 357.00000

Trial Group Type

group_type Group_Count
Experimental 1052
Active Comparator 84
NA 84
Other 25
No Intervention 20
Placebo Comparator 13
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 569
Parallel Assignment 189
NA 37
Sequential Assignment 22
Crossover Assignment 7
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 783
Supportive Care 21
Prevention 10
Basic Science 6
Other 3
Diagnostic 1
Health Services Research 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 24
France 8
Italy 8
Russian Federation 5
Greece 3
Korea, Republic of 3
Argentina 2
Canada 2
Israel 2
NA 2
Spain 2
Austria|Germany|Switzerland 1
Czechia 1
Finland 1
Germany 1
Hungary 1
India 1
Ireland|United Kingdom 1
Italy|Switzerland 1
Japan 1
Serbia 1
Sweden 1
Switzerland 1
United Kingdom 1
United States|Australia|Canada|New Zealand|Puerto Rico|Switzerland 1
United States|Australia|Canada|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 38
2 3
3 3
4 1
5 4
6 2
8 1
9 1
11 1
13 2
14 2
15 2
16 1
17 1
18 1
25 1
34 1
35 1
39 1
41 1
47 1
55 1
59 1
71 1
84 1
130 1
165 1
192 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 66.7500
Median 145.5000
Mean 530.6842
3rd Qu 437.5000
Max 4000.0000

Observation Model

observational_model Study_Count
Cohort 50
Case-Only 9
Other 6
Case-Control 5
Family-Based 3
NA 2
Case Control 1

Time Perspective

time_perspective Study_Count
Prospective 55
Retrospective 10
Cross-Sectional 4
Other 4
NA 3

Registries

Studies by Country

Country Study_Count
United States 4
France 2
NA 2
China 1
Czechia 1
Turkey 1

Sites per Study

Site_count Study_Count
1 7
2 2
11 1
192 1

Enrollment Metrics

Measure Registries
Min 198.000
1st Qu 328.000
Median 1000.000
Mean 2193.909
3rd Qu 2897.500
Max 10000.000

Registry Model

observational_model Study_Count
Cohort 9
Other 2

Time Perspective

time_perspective Study_Count
Prospective 9
Cross-Sectional 1
Other 1

Follow-up

target_duration Study_Count
10 Years 4
2 Years 3
1 Year 1
12 Months 1
3 Years 1
5 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03375619 Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells https://ClinicalTrials.gov/show/NCT03375619 Recruiting Medical College of Wisconsin 2020-08-01
NCT03374137 Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT03374137 Recruiting Hoffmann-La Roche 2020-09-30
NCT03582098 Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland https://ClinicalTrials.gov/show/NCT03582098 Completed Gilead Sciences 2019-03-26
NCT03342144 Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting https://ClinicalTrials.gov/show/NCT03342144 Recruiting AbbVie 2022-12-31
NCT03316209 Identification of Occupational Exposures in Acute Hematologic Malignancy https://ClinicalTrials.gov/show/NCT03316209 Recruiting Centre Hospitalier Intercommunal Creteil 2020-03-31
NCT03294980 Chronic Lymphoid Leukaemia Observatory in Finistere Area, France https://ClinicalTrials.gov/show/NCT03294980 Recruiting University Hospital, Brest 2025-11-30
NCT03289182 An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin’s Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) https://ClinicalTrials.gov/show/NCT03289182 Active, not recruiting Hoffmann-La Roche 2020-10-26
NCT03231579 Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study https://ClinicalTrials.gov/show/NCT03231579 Completed Carevive Systems, Inc. 2018-11-01
NCT03059251 Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina https://ClinicalTrials.gov/show/NCT03059251 Completed Hoffmann-La Roche 2019-03-30
NCT02915224 A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities https://ClinicalTrials.gov/show/NCT02915224 Active, not recruiting Hoffmann-La Roche 2020-04-30
NCT02842229 A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms https://ClinicalTrials.gov/show/NCT02842229 Completed Celgene 2017-02-02
NCT02827617 Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02827617 Recruiting Oncology Institute of Southern Switzerland 2021-02-28
NCT02767388 Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery https://ClinicalTrials.gov/show/NCT02767388 Completed University of Nebraska 2017-12-11
NCT02582320 Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program https://ClinicalTrials.gov/show/NCT02582320 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT01087333 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment https://ClinicalTrials.gov/show/NCT01087333 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00131014 Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies https://ClinicalTrials.gov/show/NCT00131014 Recruiting Dana-Farber Cancer Institute 2023-01-31
NCT00039676 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer https://ClinicalTrials.gov/show/NCT00039676 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02520895 Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02520895 Completed Hospices Civils de Lyon 2013-10-31
NCT02491398 Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia https://ClinicalTrials.gov/show/NCT02491398 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-10-31
NCT02461316 Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02461316 Completed Hoffmann-La Roche 2011-12-31
NCT02414022 Economic Analysis of Alliance A041202 CLL Study https://ClinicalTrials.gov/show/NCT02414022 Active, not recruiting Canadian Cancer Trials Group 2019-04-05
NCT02381899 Observational Study in CLL Patients Receiving BR https://ClinicalTrials.gov/show/NCT02381899 Completed Czech CLL Study Group 2016-12-31
NCT02269592 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome https://ClinicalTrials.gov/show/NCT02269592 Recruiting Dana-Farber Cancer Institute 2024-12-31
NCT02110394 Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02110394 Completed Astellas Pharma Inc 2015-08-31
NCT02080884 An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02080884 Completed Hoffmann-La Roche 2016-12-19
NCT02057185 Occupational Status and Hematological Disease https://ClinicalTrials.gov/show/NCT02057185 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-03-31
NCT03310190 Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT03310190 Recruiting AbbVie 2021-06-30
NCT01832597 Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT01832597 Completed Gruppo Italiano Studio Linfomi 2010-12-31
NCT01609023 A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01609023 Completed Hoffmann-La Roche 2015-11-30
NCT01488162 An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01488162 Completed Hoffmann-La Roche 2016-10-24
NCT01460238 Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01460238 Completed Dartmouth-Hitchcock Medical Center 2018-05-31
NCT01453062 Phase IV Observational Study in Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01453062 Completed GlaxoSmithKline 2012-11-30
NCT01397916 Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) https://ClinicalTrials.gov/show/NCT01397916 Completed Tampere University Hospital 2010-12-31
NCT01395615 An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia https://ClinicalTrials.gov/show/NCT01395615 Completed Hoffmann-La Roche 2009-10-31
NCT04407845 Atrial Fibrillation in Patients Receiving Ibrutinib https://ClinicalTrials.gov/show/NCT04407845 Recruiting European Georges Pompidou Hospital 2022-05-21
NCT04290923 Determination of Blood Tumor Cells https://ClinicalTrials.gov/show/NCT04290923 Recruiting University of Zurich 2020-09-30
NCT04198415 A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) https://ClinicalTrials.gov/show/NCT04198415 Recruiting AbbVie 2022-03-31
NCT04178317 A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT04178317 Recruiting AbbVie 2026-03-25
NCT04159779 A Study of Clinical Outcomes in Relapse/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece https://ClinicalTrials.gov/show/NCT04159779 Recruiting AbbVie 2020-11-25
NCT04028531 Understanding Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT04028531 Recruiting Dana-Farber Cancer Institute 2024-09-29
NCT04016636 A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT04016636 Recruiting Fundaleu 2021-08-31
NCT03971565 Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT03971565 Recruiting Assistance Publique Hopitaux De Marseille 2021-03-18
NCT03873857 A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation https://ClinicalTrials.gov/show/NCT03873857 Recruiting AbbVie 2022-12-03
NCT03847727 Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT03847727 Active, not recruiting Pirogov Russian National Research Medical University 2019-12-03
NCT03720561 A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting https://ClinicalTrials.gov/show/NCT03720561 Active, not recruiting Janssen-Cilag S.p.A. 2021-10-31
NCT03659669 A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT03659669 Recruiting AbbVie 2024-10-31
NCT03633045 Observational Study of Ibrutinib Use in CLL https://ClinicalTrials.gov/show/NCT03633045 Recruiting Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health 2021-09-30
NCT03529227 Gazyva Infusion Reaction Investigation https://ClinicalTrials.gov/show/NCT03529227 Recruiting Healthy Future 2019-03-31
NCT03528941 The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib https://ClinicalTrials.gov/show/NCT03528941 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2020-08-31
NCT03476655 Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India https://ClinicalTrials.gov/show/NCT03476655 Completed Johnson & Johnson Private Limited 2019-05-14
NCT03436524 A Prognostic Tool for Early Stage CLL https://ClinicalTrials.gov/show/NCT03436524 Recruiting Oncology Institute of Southern Switzerland 2020-02-28
NCT03425591 A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT03425591 Recruiting Janssen-Cilag Ltd. 2022-05-22
NCT03415035 Study Venetoclax Effectiveness and Real‐Life Treatment Management in Participants With Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT03415035 Recruiting AbbVie 2022-03-30
NCT01224093 An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC) https://ClinicalTrials.gov/show/NCT01224093 Completed Hoffmann-La Roche 2014-02-28
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01178086 A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) https://ClinicalTrials.gov/show/NCT01178086 Completed Hoffmann-La Roche 2015-06-30
NCT01145469 Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy https://ClinicalTrials.gov/show/NCT01145469 Completed Eastern Cooperative Oncology Group 2010-08-01
NCT01117142 A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers https://ClinicalTrials.gov/show/NCT01117142 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT01110863 Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects https://ClinicalTrials.gov/show/NCT01110863 Completed Northwell Health 2016-02-12
NCT01110850 Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water https://ClinicalTrials.gov/show/NCT01110850 Completed Northwell Health 2018-05-31
NCT01081015 Connectâ„¢ CLL: The Chronic Lymphocytic Leukemia Disease Registry https://ClinicalTrials.gov/show/NCT01081015 Completed Celgene 2017-12-31
NCT01072240 An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01072240 Completed Hoffmann-La Roche 2011-06-30
NCT01030913 B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression https://ClinicalTrials.gov/show/NCT01030913 Recruiting Northwell Health 2021-01-31
NCT01028430 B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging https://ClinicalTrials.gov/show/NCT01028430 Recruiting Northwell Health 2021-01-31
NCT01005368 Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01005368 Active, not recruiting Alliance for Clinical Trials in Oncology 2100-01-31
NCT01000753 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01000753 Active, not recruiting Children’s Oncology Group 2007-06-01
NCT00923507 Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) https://ClinicalTrials.gov/show/NCT00923507 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00898079 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898079 Completed Children’s Oncology Group 2018-06-30
NCT00889031 Protocol to Obtain Blood Samples for Leukemia Research https://ClinicalTrials.gov/show/NCT00889031 Completed Dartmouth-Hitchcock Medical Center 2018-03-09
NCT00626496 Family Study of Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT00626496 Recruiting Mayo Clinic 2025-12-31
NCT00569842 Investigation of the Cylex® ImmuKnow® Assay https://ClinicalTrials.gov/show/NCT00569842 Completed Indiana University 2010-02-28
NCT00513175 Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia https://ClinicalTrials.gov/show/NCT00513175 Completed University of California, San Francisco NA
NCT00503256 Genetic Study of Chronic Lymphocytic Leukemia Families https://ClinicalTrials.gov/show/NCT00503256 Active, not recruiting M.D. Anderson Cancer Center 2019-09-30
NCT00481858 Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis https://ClinicalTrials.gov/show/NCT00481858 Completed KineMed 2010-07-31
NCT00344825 Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL) https://ClinicalTrials.gov/show/NCT00344825 Completed Sanofi 2006-11-30
NCT00159003 Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel https://ClinicalTrials.gov/show/NCT00159003 Completed Hadassah Medical Organization 2017-07-01

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04342117 Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL https://ClinicalTrials.gov/show/NCT04342117 Recruiting Verastem, Inc. 2023-04-30
NCT03197259 Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study https://ClinicalTrials.gov/show/NCT03197259 Recruiting Izmir Hematologic Diseases and Cancer Research Help Association 2020-01-01
NCT02869529 Institut Paoli Calmettes Chronic Lymphatic Leukemia Database https://ClinicalTrials.gov/show/NCT02869529 Recruiting Institut Paoli-Calmettes 2030-01-31
NCT02582879 informCLLâ„¢: A Disease Registry for Patients With Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02582879 Active, not recruiting Pharmacyclics LLC. 2021-10-31
NCT02553304 Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients https://ClinicalTrials.gov/show/NCT02553304 Active, not recruiting National Health Research Institutes, Taiwan 2019-01-25
NCT02298816 B-Cell Hematologic Malignancy Vaccination Registry https://ClinicalTrials.gov/show/NCT02298816 Enrolling by invitation Aurora Health Care 2024-12-31
NCT01890486 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen https://ClinicalTrials.gov/show/NCT01890486 Recruiting Wake Forest University Health Sciences 2023-05-31
NCT04094051 Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT04094051 Recruiting The First Affiliated Hospital with Nanjing Medical University 2020-12-31
NCT03881592 Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness https://ClinicalTrials.gov/show/NCT03881592 Recruiting Brno University Hospital 2019-06-30
NCT03502876 Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL https://ClinicalTrials.gov/show/NCT03502876 Completed French Innovative Leukemia Organisation 2018-12-31
NCT00889798 Tumor Registry of Lymphatic Neoplasia https://ClinicalTrials.gov/show/NCT00889798 Completed iOMEDICO AG 2019-08-31